Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Las Vegas Sands Corp. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B), while Las Vegas Sands Corp. trades at $36.24 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Las Vegas Sands Corp. for 72 Days on average.
| HALO | LVS | |
|---|---|---|
Market Cap | $12.58B | $23.38B |
Volume | 2,179,278 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $69.49 |
52-Week Low | $61.63 | $35.81 |
Typical Hold Time | 1 Days | 72 Days |
Enterprise Value | $14.49B | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LVS trades at $36.15, up 0.95% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $13.02B in 2025 and a net income of $1.63B, with a P/E of 13.99 suggesting reasonable valuation. Recent news highlights Sands China's community initiatives and awards, while Q2 2026 earnings missed expectations.
The investment outlook is mixed: analyst consensus is bullish with a $59.78 price target, but high debt levels and a recent earnings miss pose risks. Upside potential exists if the company maintains revenue growth and executes its stock repurchase program, though sensitivity to Macao's tourism recovery and interest rates remains a key concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
